ImmuCell vs Insight Molecular Diagnostics
ImmuCell reported revenue of $28 million in fiscal 2025, 6.7 times Insight Molecular Diagnostics' $4 million in fiscal 2025. ImmuCell's revenue grew 4.3% in its latest year, and Insight Molecular Diagnostics' grew 115.6%. ImmuCell had an operating margin of 6.0%, against -1260.8% at Insight Molecular Diagnostics. Free cash flow was $1 million at ImmuCell and −$25 million at Insight Molecular Diagnostics.
Side by side
| ImmuCell | Insight Molecular Diagnostics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $28M | $4M |
| Revenue growth | 4.3% | 115.6% |
| Revenue growth a year, last 5 years | 12.5% | 27.9% |
| Gross margin | 41.4% | 56.7% |
| Operating margin | 6.0% | −1,260.8% |
| Net margin | −3.8% | −1,238.5% |
| Free cash flow | $1M | −$25M |
| Free cash flow margin | 4.4% | −625.6% |
| Return on capital | — | — |
| Net debt to EBITDA | 1.2x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 10.5% | 133.2% |
| Last close | $11.17 | $1.66 |
| P/E at the last close | 58.8× | — |
| Insider trades, last 12 months | bought $140,146, sold $0 | bought $11.7 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmuCellInsight Molecular Diagnostics
Operating margin
Percent of revenue
ImmuCellInsight Molecular Diagnostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmuCellInsight Molecular Diagnostics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ImmuCell and Insight Molecular Diagnostics pages.